Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815897 | 0.80 | POLB (0.69) | POLBALDH1A1TGFBR1CYP1A2 | |
| SCHEMBL26176327 | 0.78 | POLB (0.68) | POLBALDH1A1MEN1KMT2ATGFBR1 | |
| SCHEMBL3765749 | 0.78 | POLB (0.68) | POLBALDH1A1MEN1KMT2ATGFBR1 | |
| SCHEMBL21729418 | 0.78 | POLB (0.38) | POLBDGAT1MEN1KMT2ATGFBR1 | |
| SCHEMBL19788243 | 0.77 | POLB (0.66) | POLBALDH1A1TGFBR1MAPTMAPK1 | |
| SCHEMBL2259799 | 0.75 | POLB (0.37) | POLBTGFBR1 | |
| SCHEMBL22521532 | 0.74 | TGFBR1 (0.41) | POLBALDH1A1DGAT1TGFBR1MAPK1 | |
| SCHEMBL13976120 | 0.74 | LMNA (0.39) | POLBDGAT1TGFBR1CYP1A2CYP2D6 | |
| SCHEMBL23511269 | 0.72 | DGAT1 (0.40) | POLBALDH1A1DGAT1MAPTRAB9A | |
| SCHEMBL22944713 | 0.72 | NPC1 (0.35) | POLBDGAT1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | POLB 2322/4885ALDH1A1 1123/4885DGAT1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.